Integra LifeSciences Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides 2019 Financial Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Integra LifeSciences (IART) Tops Q4 EPS by 3c, Revenues Beat; Offers FY19 EPS Mid-Point Guidance Above Consensus, FY19 Revenue Views Below Estimates
February 21, 2019 6:13 AM ESTIntegra LifeSciences (NASDAQ: IART) reported Q4 EPS of $0.65, $0.03 better than the analyst estimate of $0.62. Revenue for the quarter came in at $383.3 million versus the consensus estimate of $381.73 million.
Fourth Quarter 2018 HighlightsReported revenue was $383.3 million, an increase of 4.0% over the prior year, while organic sales were higher by 4.4% over the prior year;GAAP earnings per diluted share amounted to $0.29, compared to $0.56 in the prior year; fourth quarter adjusted earnings per diluted share amounted to $0.65, compared to $0.64 in... More